Discovery and preclinical development of vismodegib
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Vismodegib is the first Hedgehog (Hh) pathway inhibitor approved in the US for the treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC). It was approved by the US FDA on 30 January 2012, and by the European Commission on 12 July 2013, for the treatment of adult patients with symptomatic metastatic BCC, or locally advanced BCC inappropriate for surgery or radiotherapy. Vismodegib selectively inhibits the Hh signaling pathway, binding to and inhibiting a critical signal-transducing component of the pathway, Smoothened (SMO). Vismodegib was discovered by Genentech, Inc., under a collaboration agreement with Curis, Inc. AREAS COVERED: This article reviews the development of vismodegib from its discovery, preclinical pharmacology and validation to the clinical pharmacokinetics and validation in Phase I and II clinical investigations. We also provide a survey of other Hh pathway inhibitors in clinical development. EXPERT OPINION: The authors' experience in target-based drug discovery suggests that vismodegib's path to the clinic deserves some reflection to identify key steps that have contributed to its success. Targeting the Hh pathway with vismodegib blocks the abberant signaling caused by mutational inactivation of the negative regulator PTCH1 or mutational activation of SMO. Vismodegib gives physicians a treatment option for patients with locally advanced or metastatic BCC for whom surgery or radiation is not recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hedgehog: functions and mechanisms
Varjosalo, M., & Taipale, J. (2008) · Genes & Development · doi:10.1101/gad.1693608 · Cited by 1,217 · cited 1×
“There are three vertebrate Hh ligands that bind to the 12-pass cell surface receptor patched 1 (PTCH1), sonic Hedgehog (SHH), desert Hedgehog and Indian Hedgehog [13-15].”
BackgroundPatched acts catalytically to suppress the activity of Smoothened
Taipale, J., Cooper, M. K., Maiti, T., & Beachy, P. A. (2002) · Nature · doi:10.1038/nature00989 · Cited by 794 · cited 1×
“The mechanism by which SMO is activated upon Hh ligand binding to PTCH1 is still unknown and may involve a catalytic step as one molecule of PTCH appear to be able to repress many SMO molecules [18].”
BackgroundPrice, M. A., & Kalderon, D. (2002) · Cell · doi:10.1016/s0092-8674(02)00664-5 · Cited by 381 · cited 1×
“In the absence of Hh ligand, GLI2 and GLI3 are proteolytically processed and act largely as transcriptional repressors [24-28].”
BackgroundShaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus
Jia, J., Amanai, K., Wang, G., Tang, J., Wang, B., & Jiang, J. (2002) · Nature · doi:10.1038/nature733 · Cited by 288 · cited 1×
“In the absence of Hh ligand, GLI2 and GLI3 are proteolytically processed and act largely as transcriptional repressors [24-28].”
BackgroundWong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Self-citationShifting paradigms in Hedgehog signaling
Wang, Y., McMahon, A. P., & Allen, B. L. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.005 · Cited by 124 · cited 1×
“Hh is thought to operate as a morphogen in tissues such as the neural tube and limb bud, inducing distinct cell types in a concentration-dependent manner [2,3].”
Background
Cited by
Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
“Age, years Median 64 64 64 Range 49-82 39-84 39-84 Sex Male 31 (58) 27 (51) 58 (55) Female 22 (42) 26 (49) 48 (45) Race White 40 (77) 45 (88) 85 (83) African American 10 (19) 6 (12) 16 (16) Asian 1 (2) 0 (0) 1 (1) Other 1 (2) 0 (0) 1 (1) Missing 1 2 3 Karnofsky performance score 100 19 (36) 17 (32) 36 (34) 90 14 (26)…”
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
A highlight on Sonic hedgehog pathway
Carballo, G. B., Honorato, J. R., de Lopes, G. P. F., & Spohr, T. C. L. D. S. E. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0220-7 · Cited by 460
Meta-Selective CAr–H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy
Fan, Z., Ni, J., & Zhang, A. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03402 · Cited by 285
Medulloblastoma: Molecular understanding, treatment evolution, and new developments
Liu, X., Ding, C., Tan, W., & Zhang, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107516 · Cited by 54
Metadata
- Authors
- Gould, S. E., Low, J. A., Marsters, J. C., Robarge, K., Rubin, L. L., de Sauvage, F. J., Sutherlin, D. P., Wong, H., & Yauch, R. L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2014-05-23
- Volume
- 9
- Issue
- 8
- Pages
- 969-984
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2062038881
- Cited by
- 72
- References
- 6
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.